Related references
Note: Only part of the references are listed.Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Steven Coats et al.
CLINICAL CANCER RESEARCH (2019)
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
Peng Yuan et al.
EUROPEAN JOURNAL OF CANCER (2019)
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
M. E. Cazzaniga et al.
BREAST (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
A. Matutino et al.
CURRENT ONCOLOGY (2018)
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
Pamela A. Trail et al.
PHARMACOLOGY & THERAPEUTICS (2018)
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
David M. Goldenberg et al.
Oncotarget (2018)
Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2-metastatic breast cancer (mBC)
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2017)
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
Neelima Vidula et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N. Starodub et al.
CLINICAL CANCER RESEARCH (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options
Wael A. Harb
CANCER MANAGEMENT AND RESEARCH (2015)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Trop-2 Is a Determinant of Breast Cancer Survival
Federico Ambrogi et al.
PLOS ONE (2014)
Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer
Hong Lin et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Share Paper
